ENTITY
SMARTSCORE: 2.8/5

Incyte Corp (INCY US)

71
Analysis
Health CareUnited States
Incyte Corp is a biopharmaceutical company. The Company discovers, develops and commercializes proprietary small molecule drugs, primarily used in oncology.
more
bullishIncyte Corp
12 May 2025 07:00

Incyte Corporation: Here Are The 5 Major Factors Propelling Our ‘Outperform’ Rating!

Incyte's first-quarter 2025 earnings report presents a mixed bag of results and outlooks, offering valuable insights for investors contemplating...

Logo
192 Views
Share
bullishIncyte Corp
19 Feb 2025 06:01

Incyte: Can Opzelura Offset Jakafi’s $3.7B Patent Cliff by 2028?

Incyte Corporation's recent financial and corporate update for the fourth quarter and full year 2024 showcases a year of significant growth and...

Logo
410 Views
Share
bullishIncyte Corp
05 Dec 2024 18:00

The Takeover Buzz Around Incyte: What Makes It Irresistible to Big Pharma?

Incyte Pharmaceuticals has been the center of takeover speculation recently, with its stock rallying amid whispers of a potential...

Logo
923 Views
Share
bullishIncyte Corp
06 Nov 2024 08:00

Incyte Corporation: Will Their Focus on Oncological Innovations Pay Off? - Major Drivers

Incyte exhibited a robust performance in its third quarter of 2024, marking a notable year of growth and advancement in its drug portfolio. Total...

Logo
254 Views
Share
bullishIncyte Corp
08 Aug 2024 07:00

Incyte Corporation: A Story Of Robust Pipeline Development and Strategic Acquisitions! - Major Drivers

Incyte Corporation reported its financial performance for the second quarter of 2024 with several notable highlights and strategic decisions that...

Logo
206 Views
Share
x